LVRNA010

Developed for: Orthocoronavirinae infectious disease
Investigated by: AIM Vaccine Co., Ltd. · LiveRNA Therapeutics Inc. · Ningbo Rongan Biological Pharmaceutical Co., Ltd.

today NCT05599802 · Ph 1

202420252026

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 1	NCT05599802	Feb → May 2023	Orthocoronavirinae infectious disease	AIM Vaccine Co., Ltd.	Unknown	No outcome recorded

Every value below carries the sentence it was read from. 1 source stands behind the page.

Field	Value	Cited text
Known as	LVRNA010	“SARS-CoV-2 Variant mRNA Vaccine (LVRNA010)” NCT05599802 ↗
Modality	Messenger RNA (mRNA)	“SARS-CoV-2 Variant mRNA Vaccine” NCT05599802 ↗